Literature DB >> 19036098

Expression and function of toll like receptors in chronic lymphocytic leukaemia cells.

Marta Muzio1, Cristina Scielzo, Maria T S Bertilaccio, Michela Frenquelli, Paolo Ghia, Federico Caligaris-Cappio.   

Abstract

Mature B-cells can recognize microbial antigens via B-cell-receptor (BCR) in a specific way and via Toll-like receptors (TLR) in a costimulatory manner. A wealth of information is gathering on the possible role of antigenic stimulation in the natural history of Chronic Lymphocytic Leukaemia (CLL). However little is known regarding the repertoire and function of TLR in CLL cells. The TLR family includes 10 different transmembrane proteins devoted to recognize specific pathogen-associated molecular patterns and to alarm immunocompetent cells to trigger an immune response. Here, we studied fresh leukaemic cells for the expression pattern of TLR1 to TLR10, NOD1, NOD2 and SIGIRR (also known as TIR8). CLL cells were found to express several pattern recognition receptors including TLR1, TLR2, TLR6, TLR10, NOD1 and NOD2. The specific TLR expressed by CLL cells were functional. Leukaemic cells, upon stimulation with TLR1/2/6 ligands, such as bacterial lipopeptides, activated the nuclear factor-kappaB signalling pathway, expressed CD86 and CD25 activation molecules, and were protected from spontaneous apoptosis. These findings further support the hypothesis that CLL cells resemble antigen-activated B-cells and suggest a potential role of TLR in modulating CLL cell response in the context of specific antigen recognition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036098     DOI: 10.1111/j.1365-2141.2008.07475.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  39 in total

Review 1.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

2.  Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients.

Authors:  Eleni Arvaniti; Stavroula Ntoufa; Nikos Papakonstantinou; Tasoula Touloumenidou; Nikolaos Laoutaris; Achilles Anagnostopoulos; Klea Lamnissou; Federico Caligaris-Cappio; Kostas Stamatopoulos; Paolo Ghia; Marta Muzio; Chrysoula Belessi
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

3.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

Review 4.  Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

5.  Inflammation, the microenvironment and chronic lymphocytic leukemia.

Authors:  Federico Caligaris-Cappio
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

6.  Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Authors:  Eleonora Fonte; Andreas Agathangelidis; Daniele Reverberi; Stavroula Ntoufa; Lydia Scarfò; Pamela Ranghetti; Giovanna Cutrona; Alessandra Tedeschi; Aliki Xochelli; Federico Caligaris-Cappio; Maurilio Ponzoni; Chrysoula Belessi; Zadie Davis; Miguel A Piris; David Oscier; Paolo Ghia; Kostas Stamatopoulos; Marta Muzio
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

7.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

8.  Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.

Authors:  Stavroula Ntoufa; Anna Vardi; Nikos Papakonstantinou; Achilles Anagnostopoulos; Vassiliki Aleporou-Marinou; Chrysoula Belessi; Paolo Ghia; Federico Caligaris-Cappio; Marta Muzio; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

9.  Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells.

Authors:  Mia Eriksson; Pablo Peña-Martínez; Ramprasad Ramakrishnan; Marion Chapellier; Carl Högberg; Gabriella Glowacki; Christina Orsmark-Pietras; Talía Velasco-Hernández; Vladimir Lj Lazarević; Gunnar Juliusson; Jörg Cammenga; James C Mulloy; Johan Richter; Thoas Fioretos; Benjamin L Ebert; Marcus Järås
Journal:  Blood Adv       Date:  2017-10-18

10.  NOD2 mutations affect muramyl dipeptide stimulation of human B lymphocytes and interact with other IBD-associated genes.

Authors:  Zhenwu Lin; John P Hegarty; Gerrit John; Arthur Berg; Zhong Wang; Rishabh Sehgal; Danielle M Pastor; Yunhua Wang; Leonard R Harris; Lisa S Poritz; Stefan Schreiber; Walter A Koltun
Journal:  Dig Dis Sci       Date:  2013-05-26       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.